Stock Events

Stock Events

Caribou Biosciences 

$1.5500
110
-$0.02-1.27% 13:50 Today

Statistics

Day High
1.555
Day Low
1.54
52W High
2.84
52W Low
1.39
Volume
1,642
Avg. Volume
-
Mkt Cap
166.17M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.43
-0.37
-0.3
-0.24
Expected EPS
-0.294
Actual EPS
N/A

Financials

-1,327.4%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
11.16MRevenue
-148.13MNet Income

Analyst Ratings

8.00Average Price Target
The highest estimate is 11.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRBU. It's not an investment recommendation.
CRISPR Therapeutics
17
CRSP
Beam Therapeutics
17
BEAM
Apple
16
AAPL
NVIDIA
16
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Editas Medicine
EDIT
Mkt Cap496.06M
Editas Medicine operates in the CRISPR gene editing space, directly competing with Caribou Biosciences in developing gene-edited therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.39B
CRISPR Therapeutics is a leader in the CRISPR gene editing field, making it a direct competitor to Caribou Biosciences in gene-based medicine.
Intellia Therapeutics
NTLA
Mkt Cap1.79B
Intellia Therapeutics is another key player in the CRISPR gene editing arena, competing with Caribou Biosciences in the development of gene editing therapies.
Beam Therapeutics
BEAM
Mkt Cap3.06B
Beam Therapeutics uses base editing, a form of gene editing, positioning it as a competitor to Caribou Biosciences in the precision genetic medicine field.
Allogene Therapeutics
ALLO
Mkt Cap680.62M
Allogene Therapeutics is involved in cell therapy, particularly CAR-T, which competes with Caribou Biosciences' CRISPR-engineered cell therapies.
Fate Therapeutics
FATE
Mkt Cap297.15M
Fate Therapeutics is engaged in the development of programmed cellular immunotherapies, competing with Caribou Biosciences in the cell therapy space.
Adaptive Biotechnologies
ADPT
Mkt Cap3.87B
Adaptive Biotechnologies works on immune-driven medicine, which overlaps with Caribou Biosciences' work on engineered cell therapies.
Pacific Biosciences of California
PACB
Mkt Cap419.62M
Pacific Biosciences provides sequencing technologies that are crucial for gene editing research, indirectly competing with Caribou Biosciences by enabling gene editing advancements.

About

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Show more...
CEO
Rachel E. Haurwitz
Employees
97
Country
United States
ISIN
US1420381089

Listings

BOATS
BOATS
CRBU.BOATS
XNAS
US
CRBU

0 Comments

Share your thoughts

FAQ

What is Caribou Biosciences stock price today?▼
The current price of CRBU is $1.55 USD — it has decreased by -1.27% in the past 24 hours. Watch Caribou Biosciences stock price performance more closely on the chart.
What is Caribou Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Caribou Biosciences stocks are traded under the ticker CRBU.
Is Caribou Biosciences stock price growing?▼
CRBU stock has risen by +0% compared to the previous week, the month change is a -6.06% fall, over the last year Caribou Biosciences has showed a -14.36% decrease.
What is Caribou Biosciences market cap?▼
Today Caribou Biosciences has the market capitalization of 166.17M
When is the next Caribou Biosciences earnings date?▼
Caribou Biosciences is going to release the next earnings report on November 10, 2026.
What were Caribou Biosciences earnings last quarter?▼
CRBU earnings for the last quarter are -0.24 USD per share, whereas the estimation was -0.32 USD resulting in a +25.93% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Caribou Biosciences revenue for the last year?▼
Caribou Biosciences revenue for the last year amounts to 11.16M USD.
What is Caribou Biosciences net income for the last year?▼
CRBU net income for the last year is -148.13M USD.
How many employees does Caribou Biosciences have?▼
As of September 08, 2026, the company has 97 employees.
In which sector is Caribou Biosciences located?▼
Caribou Biosciences operates in the Health & Wellness sector.
When did Caribou Biosciences complete a stock split?▼
Caribou Biosciences has not had any recent stock splits.
Where is Caribou Biosciences headquartered?▼
Caribou Biosciences is headquartered in BERKELEY, United States.